Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA. et al, (2022), Circ Heart Fail, 15
VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.
Cheng VWT. et al, (2022), Clin Cancer Res, 28, 2385 - 2396
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Telli ML. et al, (2022), NPJ Breast Cancer, 8
Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study.
Clift AK. et al, (2022), BMJ Open, 12
Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
Scott NP. et al, (2022), Br J Cancer, 126, 598 - 605
The current status of risk-stratified breast screening.
Clift AK. et al, (2022), Br J Cancer, 126, 533 - 550
Targeting OXPHOS and the electronic transport chain in cancer; Molecular and therapeutic implications.
Greene J. et al, (2022), Semin Cancer Biol
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.
Skolariki A. et al, (2022), Explor Target Antitumor Ther, 3, 172 - 199
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Kazmi F. et al, (2021), Cochrane Database of Systematic Reviews, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI. et al, (2021), Br J Cancer, 125, 520 - 527
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Baird RD. et al, (2021), J Clin Oncol, 39, 145 - 154
Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits
Di Giovannantonio M. et al, (2020), Journal of Medical Genetics
Window of opportunity clinical trial designs to study cancer metabolism.
Aroldi F. and Lord SR., (2020), Br J Cancer, 122, 45 - 51
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
Lord SR. et al, (2019), British journal of cancer
DEBIOC: A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma
Thomas A. et al, (2019), European Journal of Cancer
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U. et al, (2019), Lancet Oncol, 20, 1124 - 1135